Helicobacter pylori infection
Conditions
Interventions
Group A:keverprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, doxycycline 100 mg twice daily, colloidal bismuth pectin 300 mg twice daily for 7 days
Group B:keverprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, doxycycline 100 mg twice daily, colloidal bismuth pectin 300 mg twice daily for 14days
Sponsors
NanJing First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years; 2. Positive H. pylori status confirmed by 13C- or 14C-urea breath test and no prior history of eradication therapy; 3. Voluntary participation and provision of written informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergy to any study medication (e.g., penicillin, amoxicillin, doxycycline, keverprazan); 2. Confirmed active peptic ulcer disease; 3. Prior history of H. pylori eradication treatment; 4. Use of antibiotics or bismuth agents within 4 weeks before treatment initiation, or use of H2-receptor antagonists or proton pump inhibitors within 2 weeks; 5. Current use of corticosteroids, nonsteroidal anti-inflammatory drugs, or anticoagulants; 6. History of esophageal or gastric surgery; 7. Pregnancy or lactation; 8. Severe comorbidities, including hepatic, cardiovascular, pulmonary, or renal disease; 9. Alcohol abuse; 10. Gastric mucosa-associated lymphoid tissue lymphoma, malignant tumors, glucose-6-phosphate dehydrogenase deficiency, peptic ulcer disease, or bronchial asthma; 11. Concurrent use of specific medications: atazanavir or rilpivirine, tricyclic antidepressants, levodopa, acetaminophen, guaifenesin/dextromethorphan, monoamine oxidase inhibitors, tramadol, or similar agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| adherence;incidence of Adverse Events; | — |
Countries
China
Contacts
Public ContactZhang Zhenyu
NanJing First Hospital
Outcome results
None listed